Seer's Proxy Filing Details Executive Equity Compensation Adjustments
Ticker: SEER · Form: DEF 14A · Filed: May 28, 2025 · CIK: 1726445
| Field | Detail |
|---|---|
| Company | Seer, Inc. (SEER) |
| Form Type | DEF 14A |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Executive Compensation, Proxy Statement, Equity Awards, SEC Filing, Corporate Governance, DEF 14A, Laboratory Analytical Instruments
Related Tickers: SEER
TL;DR
**Seer's latest proxy filing is a deep dive into executive stock awards, signaling a long-term play for management, but don't expect revenue numbers here.**
AI Summary
Seer, Inc.'s DEF 14A filing on May 28, 2025, primarily details executive compensation and equity award adjustments for the fiscal years 2022, 2023, and 2024, rather than providing a comprehensive financial overview of revenue or net income. The filing indicates a focus on the valuation and reporting of outstanding and unvested equity awards granted in prior years for both named executive officers (PEO) and non-PEO employees. Specifically, adjustments to equity awards excluding values reported in the summary compensation table were made for PEOs in 2022, 2023, and 2024, and for non-PEO NEOs across the same periods. The document highlights the company's adherence to SEC disclosure requirements for executive compensation, particularly concerning equity-based incentives. While specific dollar amounts for revenue and net income are not present in this particular filing, the detailed breakdown of equity award changes suggests a strategic outlook centered on long-term incentive alignment for its leadership and key personnel. Risks related to business changes or strategic outlook are not explicitly detailed in this compensation-focused filing.
Why It Matters
This DEF 14A filing is crucial for investors as it sheds light on Seer, Inc.'s executive compensation structure, particularly the significant role of equity awards in incentivizing leadership. Understanding how executives are compensated, especially through stock, can influence investor confidence and signal management's long-term commitment. For employees, these disclosures can impact morale and perceptions of fairness in compensation practices. In the competitive laboratory analytical instruments sector, transparent and well-structured compensation plans are vital for attracting and retaining top talent, directly affecting the company's ability to innovate and compete against rivals like Thermo Fisher Scientific and Danaher Corporation.
Risk Assessment
Risk Level: low — The risk level is low because this DEF 14A filing is a routine disclosure of executive compensation and equity award adjustments, not an announcement of significant operational changes or financial distress. It primarily focuses on compliance with SEC reporting requirements for compensation, specifically detailing equity awards for 2022, 2023, and 2024, which does not inherently introduce new financial or operational risks.
Analyst Insight
Investors should review the detailed equity compensation figures to understand how Seer, Inc. incentivizes its leadership and assess potential dilution from stock awards. This information should be considered alongside the company's broader financial statements to form a complete picture of its financial health and governance practices.
Key Numbers
- 2025-05-28 — Filing Date (Date the DEF 14A was filed by Seer, Inc.)
- 0000950170-25-078352 — Accession Number (Unique identifier for the SEC filing)
- 20 — Public Document Count (Number of public documents associated with this filing)
- 2024-01-01 — Start of Fiscal Year for Equity Awards (Beginning of the period for which equity awards are reported for PEOs and Non-PEO NEOs)
- 2024-12-31 — End of Fiscal Year for Equity Awards (End of the period for which equity awards are reported for PEOs and Non-PEO NEOs)
- 1934 Act — SEC Act (The Securities Exchange Act under which the filing is made)
- 001-39747 — SEC File Number (The SEC file number for Seer, Inc.)
- 25995653 — Film Number (The film number associated with the filing)
- 3826 — SIC Code (Standard Industrial Classification for Laboratory Analytical Instruments)
- DE — State of Incorporation (Delaware, where Seer, Inc. is incorporated)
Key Players & Entities
- Seer, Inc. (company) — Registrant in DEF 14A filing
- SEC (regulator) — Securities and Exchange Commission
- Redwood City (company) — City of Seer, Inc.'s business address
- CA (company) — State of Seer, Inc.'s business address
- 0001726445 (company) — Central Index Key (CIK) for Seer, Inc.
- 3800 Bridge Parkway, Suite 102 (company) — Street address for Seer, Inc.
- 94065 (company) — ZIP code for Seer, Inc.'s business address
- 650-453-0000 (company) — Business phone for Seer, Inc.
- Seer Biosciences, Inc. (company) — Former name of Seer, Inc.
- 20171226 (dollar_amount) — Date of name change for Seer Biosciences, Inc.
FAQ
What is the primary purpose of Seer, Inc.'s DEF 14A filing?
The primary purpose of Seer, Inc.'s DEF 14A filing is to provide a definitive proxy statement to shareholders, detailing matters to be voted upon at the annual meeting, including executive compensation and equity award adjustments for the fiscal years 2022, 2023, and 2024.
Does Seer, Inc.'s DEF 14A filing include revenue and net income figures?
No, Seer, Inc.'s DEF 14A filing primarily focuses on executive compensation and equity award adjustments, not a comprehensive financial overview including revenue and net income figures. These financial details are typically found in other filings like 10-K or 10-Q reports.
What periods do the equity award adjustments in Seer, Inc.'s DEF 14A cover?
The equity award adjustments detailed in Seer, Inc.'s DEF 14A filing cover the fiscal years 2022, 2023, and 2024, specifically from January 1st to December 31st for each respective year, for both named executive officers (PEO) and non-PEO NEOs.
How does Seer, Inc. classify its industry according to the SEC filing?
According to the SEC filing, Seer, Inc. is classified under the Standard Industrial Classification (SIC) code 3826, which corresponds to 'Laboratory Analytical Instruments'.
What is the significance of equity awards for Seer, Inc.'s executives?
Equity awards are a significant component of Seer, Inc.'s executive compensation, designed to align the interests of executives with those of shareholders by incentivizing long-term performance and company value creation. The DEF 14A details adjustments to these awards.
Where is Seer, Inc. incorporated?
Seer, Inc. is incorporated in the state of Delaware, as indicated in its DEF 14A filing.
What was Seer, Inc.'s former company name?
Seer, Inc.'s former company name was Seer Biosciences, Inc., with the name change occurring on December 26, 2017.
What is the business address for Seer, Inc.?
The business address for Seer, Inc. is 3800 Bridge Parkway, Suite 102, Redwood City, CA 94065, with a business phone number of 650-453-0000.
Why is understanding executive compensation important for Seer, Inc. investors?
Understanding executive compensation, particularly equity awards, is important for Seer, Inc. investors as it provides insight into the company's governance, how management is incentivized, and potential dilution from stock-based compensation, all of which can impact shareholder value.
What type of SEC filing is Seer, Inc.'s 0000950170-25-078352?
Seer, Inc.'s 0000950170-25-078352 is a Definitive Proxy Statement, filed as a DEF 14A, which is a standard filing under the Securities Exchange Act of 1934.
Industry Context
Seer, Inc. operates in the Laboratory Analytical Instruments sector (SIC Code 3826). This industry is characterized by innovation in scientific instrumentation, requiring significant R&D investment and adherence to stringent quality and regulatory standards. Competition often comes from established players and emerging companies developing advanced diagnostic and analytical technologies.
Regulatory Implications
The filing underscores Seer, Inc.'s compliance with SEC regulations, particularly Rule 14a regarding proxy solicitations and executive compensation disclosures. Adherence to these rules is critical for maintaining investor confidence and avoiding potential penalties.
What Investors Should Do
- Review the detailed breakdown of equity award adjustments for PEOs and Non-PEO NEOs to understand long-term incentive alignment.
- Note the absence of detailed financial performance metrics (revenue, net income) in this specific filing, which is compensation-focused.
Key Dates
- 2025-05-28: Filing of DEF 14A — Indicates the company's adherence to SEC disclosure requirements for executive compensation and equity awards.
- 2024-01-01: Start of Fiscal Year for Equity Awards Reporting — Marks the beginning of the period for which equity awards for PEOs and Non-PEO NEOs are detailed in the filing.
- 2024-12-31: End of Fiscal Year for Equity Awards Reporting — Marks the end of the period for which equity awards for PEOs and Non-PEO NEOs are detailed in the filing.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC, typically used to solicit shareholder votes on important corporate matters, including executive compensation. (This filing specifically details executive compensation and equity award adjustments for Seer, Inc.)
- PEO
- Principal Executive Officer, referring to the highest-ranking executive in a company. (The filing discusses adjustments to equity awards for PEOs for the fiscal years 2022, 2023, and 2024.)
- Non-PEO NEO
- Non-Principal Executive Officer Named Executive Officer. These are other highly compensated executive officers of the company. (The filing details adjustments to equity awards for these individuals for the fiscal years 2022, 2023, and 2024.)
- Equity Awards
- Awards granted to employees in the form of company stock or options to purchase stock, often used as a form of compensation and incentive. (The DEF 14A focuses on the valuation and reporting of outstanding and unvested equity awards.)
- Summary Compensation Table
- A table required by the SEC that summarizes the compensation of the company's named executive officers for the last three fiscal years. (The filing notes adjustments to equity awards excluding values already reported in this table.)
Year-Over-Year Comparison
This DEF 14A filing, dated May 28, 2025, focuses on executive compensation and equity award adjustments for fiscal years 2022-2024. Unlike a typical 10-K or 10-Q, it does not provide year-over-year comparisons of revenue, net income, or margins. The primary comparison point is the internal adjustments made to equity awards across the reported periods for named executive officers.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 28, 2025 regarding Seer, Inc. (SEER).